Home
/
KIORA PHARMACEUTICALS INC
/
Financials
/
Quarterly
KIORA PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that KIORA PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 7, 2025
Q2
2025
Jun 30, 2025
$0
Aug 8, 2025
Q1
2025
Mar 31, 2025
$0
May 9, 2025
Q3
2025
Sep 30, 2024
$0
Nov 7, 2025
Q2
2025
Jun 30, 2024
$20.0K
Aug 8, 2025
Q1
2025
Mar 31, 2024
$16.00M
May 9, 2025
Q3
2024
Sep 30, 2023
$0
Nov 8, 2024
Q2
2024
Jun 30, 2023
$0
Aug 9, 2024
Q1
2024
Mar 31, 2023
$0
May 10, 2024
Q2
2019
Jun 30, 2019
$0
Aug 8, 2019
Q1
2019
Mar 31, 2019
$2.69M
May 8, 2019
Q3
2018
Sep 30, 2018
$314.5K
Nov 13, 2018
Q2
2019
Jun 30, 2018
$242.0K
Aug 8, 2019
Q1
2019
Mar 31, 2018
$1.10M
May 8, 2019
Q3
2018
Sep 30, 2017
$74.7K
Nov 13, 2018
Q2
2018
Jun 30, 2017
$148.3K
Aug 3, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2020
$0
Nov 9, 2020
Q2
2020
Jun 30, 2020
$0
Aug 6, 2020
Q1
2020
Mar 31, 2020
$0
May 6, 2020
Q3
2020
Sep 30, 2019
$0
Nov 9, 2020
Q2
2020
Jun 30, 2019
$0
Aug 6, 2020
Q1
2020
Mar 31, 2019
$2.69M
May 6, 2020
Q3
2019
Sep 30, 2018
$314.5K
Nov 7, 2019
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$1.10M
May 11, 2018
Q3
2017
Sep 30, 2017
$74.7K
Nov 14, 2017
Q2
2017
Jun 30, 2017
$148.3K
Aug 4, 2017
Q1
2018
Mar 31, 2017
$184.5K
May 11, 2018
Q3
2017
Sep 30, 2016
$274.3K
Nov 14, 2017
Q2
2017
Jun 30, 2016
$234.6K
Aug 4, 2017
Q1
2017
Mar 31, 2016
$0
May 5, 2017
Q3
2016
Sep 30, 2015
$0
Nov 1, 2016
Q2
2016
Jun 30, 2015
$0
Aug 10, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$26.8K
Nov 7, 2025
Q2
2025
Jun 30, 2025
($2.15M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($2.19M)
May 9, 2025
Q3
2025
Sep 30, 2024
($3.41M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($2.22M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
$13.45M
May 9, 2025
Q3
2024
Sep 30, 2023
($5.76M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($2.61M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($1.87M)
May 10, 2024
Q3
2023
Sep 30, 2022
($5.12M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($2.40M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($3.57M)
May 9, 2023
Q3
2022
Sep 30, 2021
($3.03M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($2.54M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($2.01M)
Jul 8, 2022
Q3
2021
Sep 30, 2020
($2.01M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($1.72M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($1.95M)
May 12, 2021
Q3
2020
Sep 30, 2019
($3.43M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($1.84M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($794.4K)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($2.40M)
Aug 8, 2025
Q1
2025
Mar 31, 2025
($2.33M)
May 9, 2025
Q3
2025
Sep 30, 2024
($3.60M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($2.54M)
Aug 8, 2025
Q1
2025
Mar 31, 2024
$13.22M
May 9, 2025
Q3
2024
Sep 30, 2023
($5.92M)
Nov 8, 2024
Q2
2024
Jun 30, 2023
($2.63M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($1.92M)
May 10, 2024
Q3
2023
Sep 30, 2022
($3.70M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($2.40M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($3.57M)
May 9, 2023
Q3
2022
Sep 30, 2021
($3.04M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($2.82M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($2.01M)
Jul 8, 2022
Q3
2021
Sep 30, 2020
($2.01M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($1.72M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($1.97M)
May 12, 2021
Q3
2020
Sep 30, 2019
($3.45M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($1.87M)
Aug 6, 2020